UK School Girls Will Not Benefit From The World's Leading Four-type Human Papillomavirus (HPV) Vaccine, Gardasil(R) - Sanofi Pasteur MSD Statement
"We regret that school girls in the UK, unlike most of their peers in Western Europe, the USA, Australia, New Zealand and Canada, will not benefit from the unmatched cervical cancer protection and additional benefits provided by the world's leading HPV vaccine, Gardasil®", comments Dr Nicholas Kitchin, UK Medical Director, Sanofi Pasteur MSD.
Two years after its first launch in June 2006, Gardasil® is today the HPV vaccine of choice across the world with more than 26 million doses distributed* and 95% global market share. Countries like Australia, New Zealand, Canada, France and Switzerland have chosen Gardasil® preferentially or exclusively for their vaccination campaigns or recommendations.
In addition to protection from cervical cancer, Gardasil® provides protection from precancerous cervical, vulval and vaginal lesions (an extension to the licence following a recent CHMP positive opinion) and from genital warts caused by virus types targeted by the vaccine. The four HPV types 6, 11, 16 and 18 together cause the vast majority of cervical cancer and other HPV-related genital diseases. 1,2,3
Patrick Poirot, Vice President for Medical and Scientific Affairs at Sanofi Pasteur MSD concludes: "With strong global endorsement from regulators, health authorities and physicians and with a very favourable cost-benefit profile, Gardasil® will continue to be the HPV vaccine of choice for girls and women worldwide".
The leading HPV vaccine
In all other tenders awarded to date in Western Europe†, health authorities have chosen Gardasil® for about 80% of the population covered. Gardasil® is, or will be, used exclusively for campaigns in the USA, Australia, New Zealand, Canada and Switzerland‡. The French authorities recommend the preferential use of Gardasil®.4 Where doctors can choose between the two vaccines§, more than 9 out 10 doctors worldwide choose Gardasil®.
Cost-effectiveness, early benefits and quick return on investment
The cost-effectiveness ratio (CER) of routine vaccination with Gardasil® at 12 years of age is estimated to be £5,890 per Quality Adjusted Life Year (QALY**); the CER including a catch-up programme to 17 years of age is £5,971/QALY gained. This is within the lower part of the range typically regarded as cost-effective in the United Kingdom (QALY
Scoala de fete Marea Britanie nu va beneficia de cei mai importanti patru Papillomavirus tip uman (HPV) vaccin, Gardasil (R) - Sanofi Pasteur MSD Statement - UK School Girls Will Not Benefit From The World's Leading Four-type Human Papillomavirus (HPV) Vaccine, Gardasil(R) - Sanofi Pasteur MSD Statement - articole medicale engleza - startsanatate